Table 2. Treatment-naive patients who... | American Society of Hematology

Table 2.

Treatment-naive patients who did not respond to immunotherapy

Patient	Disease duration prior to treatment	Transfusions prior to treatment, no.	Treatment type	MCF ratio
1	3.5 mo	4	ATG/CSA	1
2	5 mo	19	ATG/CSA	0.58
3	3 mo	4	ATG/CSA	1
4	10 y	2	CTX	0.9
5	3 mo	3	ATG/CSA	1
6	8 y	4	ATG/CSA	0.52
7	4 mo	20	ATG/CSA	0.36
8	8 y	3	CTX	0.54
9	2.5 mo	4	CTX	0.28
10	4 y	11	ATG/CSA	0.58
11	3 mo	2	ATG/CSA	0.39
12	3 mo	9	ATG/CSA	1
13	3 mo	3	ATG/CSA	1
14	3 wk	3	ATG/CSA	1
15	1 mo	2	ATG/CSA	0.7
16	2 wk	4	ATG/CSA	0.8
17	3 mo	5	ATG/CSA	1.2
18	2 mo	4	ATG/CSA	1
19	1 mo	6	ATG/CSA	1.1
20	2 mo	1	ATG/CSA	0.66
21	2 wk	8	ATG/CSA	0.89
22	2 wk	3	ATG/CSA	0.7
23	3 wk	4	ATG/CSA	2.8^*
24	2 wk	5	ATG/CSA	1.0

Patient	Disease duration prior to treatment	Transfusions prior to treatment, no.	Treatment type	MCF ratio
1	3.5 mo	4	ATG/CSA	1
2	5 mo	19	ATG/CSA	0.58
3	3 mo	4	ATG/CSA	1
4	10 y	2	CTX	0.9
5	3 mo	3	ATG/CSA	1
6	8 y	4	ATG/CSA	0.52
7	4 mo	20	ATG/CSA	0.36
8	8 y	3	CTX	0.54
9	2.5 mo	4	CTX	0.28
10	4 y	11	ATG/CSA	0.58
11	3 mo	2	ATG/CSA	0.39
12	3 mo	9	ATG/CSA	1
13	3 mo	3	ATG/CSA	1
14	3 wk	3	ATG/CSA	1
15	1 mo	2	ATG/CSA	0.7
16	2 wk	4	ATG/CSA	0.8
17	3 mo	5	ATG/CSA	1.2
18	2 mo	4	ATG/CSA	1
19	1 mo	6	ATG/CSA	1.1
20	2 mo	1	ATG/CSA	0.66
21	2 wk	8	ATG/CSA	0.89
22	2 wk	3	ATG/CSA	0.7
23	3 wk	4	ATG/CSA	2.8^*
24	2 wk	5	ATG/CSA	1.0

Patient was scored as positive, remained positive following treatment, but responded to second course of immunotherapy.